June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Telmisartan increases the levels of brain derived neurotrophic factor and glutathione in the retina of streptozotocin-induced diabetic rats
Author Affiliations & Notes
  • Mohammad Ola
    Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
  • Mohd Nawaz
    Ophthalmology, King Saud University, Riyadh, Saudi Arabia
  • Hatem Abuohashish
    Pharmacology&Toxicology, King Saud University, Riyadh, Saudi Arabia
  • Abdullah Alhomaida
    Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
  • Salim Al-Rejai
    Pharmacology&Toxicology, King Saud University, Riyadh, Saudi Arabia
  • Mohammed Ahmed
    Pharmacology&Toxicology, King Saud University, Riyadh, Saudi Arabia
  • Footnotes
    Commercial Relationships Mohammad Ola, None; Mohd Nawaz, None; Hatem Abuohashish, None; Abdullah Alhomaida, None; Salim Al-Rejai, None; Mohammed Ahmed, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2694. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mohammad Ola, Mohd Nawaz, Hatem Abuohashish, Abdullah Alhomaida, Salim Al-Rejai, Mohammed Ahmed; Telmisartan increases the levels of brain derived neurotrophic factor and glutathione in the retina of streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2694.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Activation of renin angiotensin system (RAS) is one of the key pathophysiological processes in diabetic retinopathy. Increase in the expression of angiotensin II type 1 receptor (AT1R) in diabetic retina has been shown to play a pivotal role in damaging neuronal component of retina, a widely recognized early feature of diabetic retinopathy. The purpose of this study is to determine the effect of telmisartan, an AT1R blocker on amelioration of reduced neurotrophic support and antioxidant status in the diabetic rat retina.

Methods: Diabetes was induced by streptozotocin (STZ) in the male Wister rats. Three weeks of diabetic rats were orally treated with telmisartan (10 mg/kg/d) for 4 weeks, and then serum and retina collected for the analyses and compared with their age matched non-diabetic control and untreated diabetic rats. The levels of brain derived neurotrophic factor (BDNF) in the serum and retina of non-diabetic, diabetic and telmisartan treated diabetic rats were measured by ELISA and glutathione by biochemical methods. The expression of BDNF and ciliary neurotrophic factor (CNTF) in retinal samples were analyzed by immunoblotting techniques. The caspase-3 activity in the retinal tissue was measured using a caspase-3 colorimetric assay kit.

Results: The level of BDNF in the serum and retina of telmisartan treated diabetic rats were found to be significantly increased compared to untreated diabetic rats: (serum, 1.33 ± 0.14 to 1.82 ± 0.25 ng/ml ; retina,16.36 ± 2.0 to 22.00 ± 2.5 pg/ml, p< 0.05). Glutathione level was increased both in the serum and retina of drug treated diabetic rats: (serum, 0.70 ± 0.07 to 0.90 ± 0.08 μM; retina, 2.27 ± 0.11 to 3.2 ± 0.45 μM/μg protein, p<0.05). The caspase-3 activity in the diabetic treated retina was significantly decreased to control level. The protein expression levels of BDNF and CNTF were increased significantly in the drug treated diabetic rat retinas compared to untreated diabetic rats.

Conclusions: AT1R blocker telmisartan increased the neurotrophic support and endogenous antioxidant glutathione both systemically and locally in the diabetic retina, and decreased signs of apoptosis in the diabetic retina, suggesting its potential role as a neuroprotective agent in diabetic retinopathy.

Keywords: 499 diabetic retinopathy • 615 neuroprotection • 690 retina: neurochemistry  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×